HIV Patients Could Pause Daily Medication for Up to Two Years with New Antibody Therapy

HIV patients may soon avoid daily medication for up to two years with a new antibody-based treatment. A trial led by Imperial College London tested a cocktail of two broadly neutralising antibodies. In a study of 68 volunteers, 75% safely paused antiretroviral therapy for at least five months. Half maintained viral control for one year, and one quarter did so for two years. Researchers plan to study those with the longest responses and explore extending benefits to more patients. Experts say this marks the first time antibody therapy has shown such long-lasting control of HIV in a randomised trial. They hope this approach could complement existing antiretroviral therapy and bring us closer to a cure. The study involved teams from Oxford University and Rockefeller University across Britain and Denmark between 2021 and 2024. Results were published in a leading medical journal.

Use The App To Win ₦1m

Stories are shared by community members. This article does not represent the official view of NaijaWorld — the author is solely responsible for its content.